Continuity of pharmaceutical supply: Difference between revisions
Expand source-linked scientific reference and navigation |
Add complete multilingual reference and language navigation |
||
| Line 1: | Line 1: | ||
<div class="wiki-language-nav" style="padding:0.75em; border:1px solid #b5c8cd; border-radius:0.5em; margin-bottom:1em;">[[Continuity of pharmaceutical supply|English]] · [[Continuity of pharmaceutical supply/uk|Українська]] · [[Continuity of pharmaceutical supply/es|Español]] · [[Continuity of pharmaceutical supply/fr|Français]] · [[Continuity of pharmaceutical supply/de|Deutsch]] · [[Continuity of pharmaceutical supply/pt|Português]]</div> | |||
Continuity of pharmaceutical supply concerns maintaining lawful and reliable access to medicines when ordinary institutional arrangements are disrupted. The legal dimension includes supply agreements, responsibilities of healthcare facilities and procedures for resolving contractual disputes. | Continuity of pharmaceutical supply concerns maintaining lawful and reliable access to medicines when ordinary institutional arrangements are disrupted. The legal dimension includes supply agreements, responsibilities of healthcare facilities and procedures for resolving contractual disputes. | ||
Latest revision as of 00:52, 12 November 2026
Continuity of pharmaceutical supply concerns maintaining lawful and reliable access to medicines when ordinary institutional arrangements are disrupted. The legal dimension includes supply agreements, responsibilities of healthcare facilities and procedures for resolving contractual disputes.
A 2021 article by Valerii Shapovalov and Olexander Sichkarenko examines forensic-pharmaceutical risks during COVID-19 restrictions. It connects medicine provision with contractual relations, force-majeure risks, possible contract amendments and civil dispute resolution. This provides a research example of how pharmaceutical care depends on legal and organizational arrangements as well as clinical knowledge.
The presence of an emergency must not be described as automatically cancelling contractual obligations. The article is historical scholarship, not an assessment of any particular present-day contract. Related topics: pharmaceutical law, organizational and legal analysis, access to medicines and institutional resilience.
Source
Shapovalov, V., & Sichkarenko, O. (2021). Forensic and pharmaceutical risks in the activities of healthcare facilities in the context of the spread of coronavirus disease (COVID-19) from the position of pharmaceutical law. SSP Modern Law and Practice, 1(1), 1–9.
See also: Terms and concepts index · Journal research map · History and research foundations.